Intelligence / Semaglutide

Semaglutide

Prescription Only
GLP-1 Agonist
Schedule
S4
Prescription Only
Enforcement
Tightening
Low Risk
Providers
12
Access: Clear
Key Facts
Schedule 4 - Prescription Only
GLP-1 receptor agonist
TGA-approved branded products available
Compounded versions under increased scrutiny
Import restrictions tightened February 2026

Overview

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes management. It is available in Australia as branded products (Ozempic, Wegovy) and through compounding pharmacies. The TGA has increased regulatory scrutiny on compounded versions following supply shortages.

Australian Scheduling

Schedule 4 (Prescription Only). TGA-approved branded products are listed on the ARTG. Compounded semaglutide is available under pharmacy compounding exemptions. Import restrictions were tightened in February 2026.

Access Pathway

Available through telehealth clinics and compounding pharmacies. Branded versions (Ozempic, Wegovy) can be prescribed by any GP. Compounded versions are available through specialised providers but face increasing regulatory scrutiny.

Regulatory Notice

For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.

News & Updates20 items
Knowledge, Attitudes and Practices on the Use of Antidiabetic Medications for Weight Loss: A Cross-Sectional Study in the Lebanese Population
Endocrinology, diabetes & metabolism15 July 2026
Déjà vu! A Case of Recurrent Metabolic Dysfunction-Associated Steatohepatitis 70 Days After Liver Transplantation
ACG case reports journal15 July 2026
Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription records
Biology methods & protocols15 July 2026
Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis
The Journal of international medical research15 July 2026
Real-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative Review
Journal of diabetes15 July 2026
Semaglutide alters behaviour and nucleus accumbens oscillatory activity in healthy mice
Molecular Brain11 July 2026
The Periprocedural Safety of Continued GLP-1 Receptor Agonist Prior to Cardiac Catheterization
American Journal of Cardiology11 July 2026
Direct effects of glucagon-like peptide-1 receptor agonists on mitochondrial function in human-derived in vitro models: a systematic review and meta-analysis
Metabolism Open11 July 2026
TAAR1 as a Potential Alternate Molecular Target to GLP-1 for Novel Anti-diabetic, Anti-obesity Medications
Handbook of Experimental Pharmacology11 July 2026
Pharmacologic Treatment for Obstructive Sleep Apnea in Older Adults
Drugs & Aging11 July 2026
Imaging in Semaglutide Study
ClinicalTrials.gov10 July 2026
Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis
Diabetes Obes Metab9 July 2026
GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis
Stem Cell Reports9 July 2026
Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients
Obstet Gynecol9 July 2026
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
ClinicalTrials.gov9 July 2026
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese - record updated
ClinicalTrials.gov8 July 2026
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
Hoffmann-La Roche7 July 2026
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Novo Nordisk A/S7 July 2026
Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study.
BMC pulmonary medicine4 July 2026
GLP-1 receptor agonists in pediatric obesity.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver4 July 2026

Are You a Practitioner?

List your clinic for free and reach patients actively searching for legal peptide access in Australia.